AbbVie | ABBV - Ebitda

Aktienkurs
210.39
Täglich Wechseln
-0.38 -0.18%
Monatlich
0.67%
Jährlich
14.33%
Q2 Prognose
197.38




Ebitda Veränderung Datum
AbbVie USD 5.37B 1.85B 2025-12
Abbott USD 3.27B 178M 2025-12
ALKERMES USD 80.26M 20.05M 2026-03
Amgen USD 5.14B 775M 2025-12
AstraZeneca USD 5.67B 1.29B 2026-03
Biogen USD 649.7M 76.5M 2026-03
BioMarin Pharmaceutical USD 146.05M 170.22M 2026-03
Bristol-Myers Squibb USD 2.88B 1.36B 2025-12
Coherus Biosciences USD -43.33M 4.7M 2025-09
Eisai JPY 30.1B 6.62B 2025-12
Eli Lilly USD 12.14B 4.26B 2025-12
Gilead Sciences USD 3.02B 1.01B 2025-12
GlaxoSmithKline GBP 2.77B 1.65B 2026-03
Infinity Pharmaceuticals USD -10.01M 1.39M 2023-06
J&J USD 7.19B 2.32B 2025-12
Medtronic USD 2.93B 482M 2025-12
Merck USD 6.3B 2.09B 2025-12
Neurocrine Biosciences USD 193.3M 25.1M 2026-03
Novartis USD 5.3B 530M 2026-03
Pacira USD 40.24M 1.53M 2026-03
Perrigo USD 141.6M 1.34B 2026-03
Pfizer USD 5.99B 5.23B 2026-03
Regeneron Pharmaceuticals USD 1.2B 718.4M 2025-12
Roche Holding CHF 12.68B 2.36B 2024-06
Sanofi EUR 3.31B 3.65B 2026-03
UCB EUR 1.6B 570M 2025-12
Ultragenyx Pharmaceutical USD -99.43M 57.35M 2025-12
United Therapeutics USD 379.5M 83.4M 2025-12
Vertex Pharmaceuticals USD 1.19B 195.3M 2026-03
Zoetis USD 939M 101M 2025-12